SIOPEN

  • International Society of Paediatric Oncology Europe Neuroblastoma

Future studies

SIOPEN is currently developing additional clinical trials.

The forthcoming VERITAS study will be designed for patients with high-risk neuroblastoma who fail to respond adequately to induction (initial) chemotherapy. These patients will receive a combination of myeloablative chemotherapy with or without MIBG therapy.

SIOPEN meetings

Forthcoming meetings:

Berlin (Germany) AGM

25-27 October 2017 

click for more information

SIOPEN

SIOPEN Verein zur Foderung der Neuroblastomforschung is an Association registered in Austria and recognised as a non-profit organisation according to the Austrian Federal Tax Code (Bundesabgabenordnung BAO). Registration number ZVR 396592912. The SIOPEN Association was officially established on 20 January 2009.

This website makes use of stock photography and images do not represent particular individuals treated by SIOPEN institutions.